203 related articles for article (PubMed ID: 16288115)
1. Clinical trial transparency: registries, databases raise questions, stir debate.
Benowitz S
J Natl Cancer Inst; 2005 Nov; 97(22):1640-1. PubMed ID: 16288115
[No Abstract] [Full Text] [Related]
2. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
3. Implementing registries and results databases of clinical trials: is there a side effect?
Dahm M; González P; Porteiro N
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):247-51. PubMed ID: 20545589
[TBL] [Abstract][Full Text] [Related]
4. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
5. Pediatric drug trials facing some obstacles.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(23):1720-1. PubMed ID: 16333025
[No Abstract] [Full Text] [Related]
6. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
7. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
8. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
9. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
10. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
11. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
12. Industry anger over stringent trial disclosure requirements.
Wadman M
Nat Rev Drug Discov; 2006 Jul; 5(7):527-8. PubMed ID: 16883642
[No Abstract] [Full Text] [Related]
13. Trials, tricks and transparency: how disclosure rules affect clinical knowledge.
Dahm M; González P; Porteiro N
J Health Econ; 2009 Dec; 28(6):1141-53. PubMed ID: 19782416
[TBL] [Abstract][Full Text] [Related]
14. European Commission considers revisions to clinical trials directive.
Mason E
J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
[No Abstract] [Full Text] [Related]
15. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
16. TG-4010 Transgene.
Cohen S; Kaufman HL
Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
[TBL] [Abstract][Full Text] [Related]
17. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
18. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
19. Clinical approval success rates for investigational cancer drugs.
DiMasi JA; Reichert JM; Feldman L; Malins A
Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial registries and clinical trial result posting: new paradigm for medical writers.
Foote M
Biotechnol Annu Rev; 2006; 12():379-86. PubMed ID: 17045200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
